Skip to content

Evidence-Based Evaluation of Huoxue Jiedu Chanling Granules as Sequential Therapy to Standard Western Medicine for Preventing Recurrence and Metastasis of Colorectal Cancer

Evidence-Based Evaluation of Huoxue Jiedu Chanling Granules as Sequential Therapy to Standard Western Medicine for Preventing Recurrence and Metastasis of Colorectal Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002590
Enrollment
Unknown
Registered
2025-12-29
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

Intervention group:Chanling Granules
Control group:Placebo (5 % active Chanling granules)

Sponsors

The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: AI (1) Patients with a confirmed pathological diagnosis of colorectal cancer who met the diagnostic criteria for the aforementioned diseases; (2) Patients who had undergone radical resection for colorectal cancer and had completed adjuvant therapy within the preceding 3 months; or those within 6 months post-operation who had not received any postoperative adjuvant therapy; (3) TNM stage classified as high-risk stage II, stage III, or stage IVA (resectable synchronous metastases); (4) Age = 18 years; (5) Traditional Chinese medicine syndrome differentiation consistent with internal accumulation of stasis and toxin pattern; (6) No evidence of local recurrence or distant metastasis as confirmed by imaging; (7) Signed informed consent form.

Exclusion criteria

Exclusion criteria: (1) History of other malignant tumors within the past five years; (2) Patients with severe primary diseases such as cardiovascular and cerebrovascular diseases, hepatic or renal insufficiency, or hematopoietic system disorders; (3) Individuals allergic to any component of the Chinese herbal medicine; (4) Any unstable condition or factor that may compromise patient safety or study compliance, including but not limited to childbearing potential, pregnancy, lactation, or psychiatric disorders such as depression, manic-depressive disorder, obsessive-compulsive disorder, or schizophrenia; (5) Patients deemed by the investigator to be unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
2-year recurrence/metastasis rate;

Secondary

MeasureTime frame
Progression-free survival;1-,3-year recurrence/metastasis rate;Quality of life;

Countries

China

Contacts

Public ContactWenyu WU

The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

250005736@qq.com138851283000

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026